There’s Little Incentive To Develop Antibiotics, But Does TB Drug’s Recent Success Story Herald New Model For Future?

In recent decades, pharmaceutical funding has been directed primarily toward drug research and development that will yield higher revenue, such as cancer drugs. But TB Alliance relied on donors from across the world to fund the development of its new tuberculosis antibiotic, and experts wonder if this is a path forward for new drugs. In other pharmaceutical news: the Norvartis data manipulation case continues, the FDA flexes its muscles, and a new treatment might help blood cancer patients.

from Kaiser Health News https://ift.tt/30sdf0l